Detection of Fluconazole-Resistant Candida Strains by a Disc Diffusion Screening Test
Author:
- 1 December 1999
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 37 (12) , 3856-3859
Abstract
A commercial disc diffusion test has been evaluated as a screening method for the detection of Candida species with decreased susceptibility to fluconazole. A total of 1,407 Candida strains of different species were tested, and the results were compared with the MIC results. The recently published National Committee for Clinical Laboratory Standards breakpoint criteria have been used. Isolates were classified as susceptible if the MIC for the isolates was ≤8 μg/ml, susceptible-dose dependent (S-DD) if the MIC was 16 to 32 μg/ml, and resistant if the MIC was ≥64 μg/ml. All 77 resistant strains and 121 of 122 S-DD strains had fluconazole zone diameters of ≤21 mm, and most of the strains (91%) had zone diameters of ≤15 mm. It was not possible to distinguish between resistant and S-DD strains by the disc test. Among a total of 1,208 strains found to be susceptible by the microdilution method, 49 (4.1%) yielded fluconazole zone sizes of ≤21 mm and would have been misclassified as resistant or S-DD strains on the basis of the disc test. For the majority (86%) of these 49 strains the fluconazole MIC was 8 μg/ml. The fluconazole disc test is recommended as a simple and reliable screening test for the detection of Candida strains with decreased susceptibility to fluconazole. Fluconazole MICs should be determined for strains found to be resistant by the disc test. The reason for confirmatory testing is twofold: to determine if isolates are resistant or S-DD, since the disc test does not make this distinction, and to identify fluconazole-susceptible strains that are found to be falsely resistant by the fluconazole disc test.Keywords
This publication has 15 references indexed in Scilit:
- Fluconazole disc diffusion testing for the routine laboratory.Journal of Antimicrobial Chemotherapy, 1997
- When shouldCandida isolates be tested for susceptibility to azole antifungal agents?European Journal of Clinical Microbiology & Infectious Diseases, 1997
- Analysis of 281,797 Consecutive Blood Cultures Performed over an Eight-Year Period: Trends in Microorganisms Isolated and the Value of Anaerobic Culture of BloodClinical Infectious Diseases, 1997
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Fluconazole disk diffusion procedure for determining susceptibility of Candida speciesJournal of Clinical Microbiology, 1996
- Antifungal susceptibility pattern of non-albicans Candida species & distribution of species isolated from Candidaemia cases over a 5 year period.1996
- Fungemia: An increasing problem in a Danish university hospital 1989 to 1994Clinical Microbiology and Infection, 1995
- Nosocomial Candidemia: Risk Factors and Attributable MortalityClinical Infectious Diseases, 1995
- Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study GroupAntimicrobial Agents and Chemotherapy, 1993
- Laboratory identification and sensitivity testing of yeast isolatesActa Odontologica Scandinavica, 1990